Bionor has acquired its 3rd HIV vaccine candidate, Vacc-CRX.
Oslo, January 10, 2019 The acquisition is in the form of an exchange of patents and rights between Bionor and Immunor AS. During Bionor’s equity raise in December 2017, Bionor […]
Change of name to Bionor Holding AS
Oslo, January 29.1.2018 In an Extraordinary General Meeting today, the shareholders unanimously adopted to change the name of the company from Bionor Pharma AS to Bionor Holding AS. The change […]
Birger Sørensen and his team closed the purchase and funding of Bionor today
Oslo, December 8, 2017 Bionor was purchased by the founder of Bionor AS, Birger Sørensen and his team, on September 28, 2017 with financial closing as of today. With the […]